Abstract: Objective The aim of this study was to evaluate the efficacy and safety of combination therapy with docetaxel and nedaplatin in advanced esophageal cancer.Methods 45 patients were included in the study(30 male,15 female);median age:54 years(range 37-72);37 cases of squamous cell carcinoma,8 cases of adenocarcinoma.10 patients never received treatment,35 re-treatment patients who received more than one chemotherapy.Patients received docetaxel 37.5mg/ m² on day 1、8,nedaplatin 80mg/ m² on day 2,every 3 weeks.Evaluate the efficacy and toxicity every 2 cycles according to WHO criteria.Results A total of 177 chemotherapy cycles was administered.The median number of cycles was 3.9(range 1-6).The response rate was 37.8% including one complete response,22 partial response.Initial treatment or retreatment,stage,histological type had no effect on short-term effect.Common toxicity was neutropenia.Conclusion the combination chemotherapy of docetaxel and nedaplatin is an active regimen with moderate toxicity in the treatment of patients with progression esophageal cancer.